QUOTED. 15 December 2020. Jessica Schubel.
Executive Summary
Experts speculate a Good Guidance Practices regulation from the US HHS will delight the medtech industry but see FDA pushback. Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities, expressed concerns.
"I think everyone is a loser in terms of having this reg finalized, because it’s implementing a process that is totally unnecessary.” – Jessica Schubel, senior policy analyst, Center on Budget and Policy Priorities
- Find out more: Lauded By Industry, Loathed By FDA? New HHS ‘Good Guidance’ Rule Likely Ruffling Feathers